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Reversible epigenetic changes that alter gene expression are a characteristic of many cancers 
and other diseases. Biotech companies are taking note and are starting to develop new drugs to 
reverse such pathogenic “epimutations.”It was the mysterious transformation of 
precancerous cells into muscle cells that 
got Peter Jones involved in epigenetics, 
the study of heritable information that 
does not affect the sequence of DNA. 
“It was a Fleming-like experience,” says 
Jones, currently the director of the Nor-
ris Comprehensive Cancer Center at 
the University of Southern California. 
Back in 1980, an assistant spotted what 
appeared to be mold in a culture dish 
of immortalized mouse embryonic cells 
treated with the chemical 5-azacytidine. 
“It was the most massive muscle cell 
colony ever. It was so big, that it looked 
like a mold,” reminisces Jones. 5-azacy-
tidine had transformed the precancerous 
cells into muscle cells, but how?
It took Jones and others a decade 
to figure it out. Azacytidine is able to 
replace the base cytosine in DNA but 
cannot carry epigenetic marks such as 
methyl groups. Methyl groups are added 
to certain cytosines by the enzyme DNA 
methyltransferase, rendering genes 
inaccessible to transcription factors and 
silencing their expression. During tumor 
formation, DNA methylation can be 
misregulated. This may lead to spread-
ing of methyl marks across the genome 
and the silencing of tumor suppressor 
genes as well as other genes encoding, 
for example, MyoD, which regulates the 
differentiation of muscle cells. In Jones’ 
experiment, treating precancerous cells 
with azacytidine resulted in demethyla-
tion of the MyoD gene followed by its 
reactivation and the differentiation of 
these cells into muscle cells. Jones real-
ized that azacytidine could be used to 
treat tumors by reversing pathogenic 
epigenetic marks or “epimutations” and 
reactivating the expression of tumor 
suppressor genes. In 2004, azacytidine 
(brand name Vidaza) made by Pharmion 
(now owned by Celgene) became the 
first epigenetic drug on the market, with 
worldwide sales of $165 million in 2007.Vidaza is currently used to treat 
patients with myelodysplastic syndrome 
(MDS), who have few therapeutic options 
and develop acute leukemia. “5-azacy-
tidine is the first breakthrough for MDS 
patients,” says Ulrich Mahlknecht at 
Saar University, one of the first German 
physicians to treat cancer patients with 
azacytidine. A worldwide phase III clini-
cal trial is currently underway to test a 
related drug 5-aza-deoxycytidine or 
Dacogen (developed by the biotech 
company SuperGen and marketed by 
the Japanese pharmaceutical company 
Eisai) in elderly patients with acute myel-
oid leukemia. Mahlknecht is optimistic 
that “epigenetic cancer therapy might be 
a good choice to treat slow growing can-
cers and could be integrated into con-
ventional chemotherapy protocols.”
Investors are taking note of the epige-
netics field, and big pharma are buying 
up biotech companies that are devel-
oping promising epigenetic therapies. 
The latest deal, worth $375 million and 
announced last month, is between the 
UK pharmaceutical giant GlaxoSmith-
Kline and SuperGen. The biotech com-
panies Constellation and Epizyme, in 
Boston, Massachusetts, have raised 
$49 million and $42 million, respectively, 
since their founding last year. They aim 
to develop drugs to block new classes 
of enzymes (histone methyltransferases 
and demethylases) that methylate and 
demethylate histones rather than DNA. 
In 2008, Eisai paid $3.9 billion for MGI 
Pharma in Bloomington, Minnesota, who 
had acquired the worldwide exclusive 
rights for Dacogen from SuperGen in 
2004. Meanwhile, Syndax in Waltham, 
Massachusetts, has raised $40 million to 
develop entinostat for treating lung can-
cer, a new epigenetic drug that blocks 
another class of enzymes, called histone 
deacetylases (HDACs), involved in epige-
netic processes. And in late 2007, Phar-
mion, who make Vidaza, was acquired Cell 139, Dby the Swiss pharma company Celgene 
for $2.9 billion. In 2004, Merck acquired 
Aton Pharma for $125 million in order 
to further develop their drug Vorinos-
tat (Zolinza), an HDAC inhibitor used to 
treat advanced lymphoma. “Epigenetic 
cancer drugs might be able to reach 
blockbuster status,” says Frank Lyko of 
the German Cancer Research Center in 
Heidelberg, because the phenomenon 
of misregulation of tumor suppressor 
genes and oncogenes due to epimuta-
tions can be found in a variety of cancer 
types. “Epigenetic changes are respon-
sible for at least 50% of gene inactivating 
events in cancer,” notes Jones. “They are 
potentially reversible, whereas genetic 
changes are not.”
The current boom in the development 
of epigenetic therapies partly reflects the 
realization that elucidating the pathogen-
esis of diseases with an environmental 
component requires understanding the 
epigenetic mechanisms involved. This 
year, the US National Institutes of Health 
(NIH) in Bethesda, Maryland, launched 
the 5 year $190 million Epigenetics Road-
map Project, with the goal of mapping 
the entire human “epigenome”—that is, 
all of the epigenetic marks within a cell 
of a given tissue type and developmental 
stage. One of the Reference Epigenome 
Mapping Centers of the NIH program is 
at the University of California, San Diego, 
where Joseph Ecker (also at the Salk 
Institute) leads a research group. Ecker 
has compared the DNA methyl marks 
across the genomes of human embry-
onic stem cells and fetal fibroblasts and 
has found marked differences. These 
and other methylomes should help to 
define the differences between normal 
and pathogenic epigenetic changes and 
whether drugs can reverse the latter with-
out interfering with the former. “Unless we 
know how these drugs affect the entire 
epigenome, we don’t really understand 
their full mechanism of action,” says ecember 11, 2009 ©2009 Elsevier Inc. 1029
Ecker. The NIH has also invested about 
$16.8 million over 5 years in the Center 
for Epigenetics of Common Human Dis-
ease at the Johns Hopkins University 
in Baltimore, Maryland. Here, Andrew 
Feinberg and his team are searching for 
pathogenic epimutations that may cause 
cancer or other diseases such as autism 
or depression. Meanwhile, Jones has 
received $9 million from the US charity 
Stand up to Cancer to develop epige-
netic cancer therapies. And in the UK, 
the Wellcome Trust has spent $4.1 million 
as part of a public-private partnership—
the Structural Genomics Consortium—
that includes GlaxoSmithKline, the NIH’s 
Chemical Genomics Center in Bethesda, 
Maryland, and the Departments of Chem-
istry and Biochemistry at the University 
of Oxford. The goal is to develop small-
molecule inhibitors against 25 proteins 
involved in epigenetic pathways. Within 
its Framework 6 program, the European 
Union has funded the Epigenome Net-
work of Excellence (NoE) comprising 81 
European research groups with €12.5 
million between 2004 and 2009. This 
program has been extended until August 
next year and will likely be continued 
thereafter but with a focus on “epigenet-
ics systems biology,” according to Jörn 
Walter of the University of Saarbrücken, 
Germany, who leads one of the epige-
netic research teams.
Lack of Specificity?
There are a number of different mecha-
nisms for the epigenetic regulation of gene 
expression. In addition to DNA methyla-
tion/demethylation, the histones of chro-
matin also may have methyl marks or 
acetyl groups added or removed. In gen-
eral, histone acetylation enables genes to 
be expressed, whereas histone methyla-
tion silences genes. HDAC inhibitors such 
as Vorinostat or entinostat, by blocking 
removal of acetyl groups from the lysine 
residues of histone tails, alter the pack-
aging of genes in chromatin such that 
those that are pathogenically silenced are 
switched back on. Vorinostat—approved 
by the US Food and Drug Administration 
(FDA) to treat lymphoma in 2006—coun-
teracts the deacetylation and repression 
of vital genes such as the tumor suppres-
sor p53. Another approved HDAC inhibi-
tor is valproic acid (Depakote), which has 
long been used to treat bipolar disease, 1030 Cell 139, December 11, 2009 ©2009 Eepilepsy, and most recently migraine. The 
investigational HDAC inhibitor entinostat 
is in several phase II clinical trials to treat 
Hodgkin’s lymphoma, leukemia and lung 
cancer. One major issue with HDAC inhib-
itors is that they target not only the lysines 
in histones but also those in other pro-
teins, leading to unwanted side effects. 
“We need to know much more about 
the mechanism of action of the different 
classes of HDACs,” says Kapil Bhalla, an 
oncologist at the Georgia Cancer Center 
in Augusta, Georgia.
But lack of specificity is also an issue 
with other epigenetic drugs. Azacytidine, 
for example, results in demethylation of 
many regions of the genome and not only 
pathogenically repressed tumor suppres-
sor genes. “It’s a mixed blessing,” says 
Rudolf Jaenisch at the Whitehead Insti-
tute in Cambridge, Massachusetts. “If you 
generally inhibit the methyltransferase, 
then you protect one tissue but you 
induce cancer in another.” Experiments 
in Jaenisch’s lab show that widespread 
demethylation of the genome could pre-
vent mice from developing colon cancer 
while increasing their chance of develop-
ing tumors of the thymus. Timothy Bestor 
of Columbia University in New York points 
out that: “The drugs under development 
and in trials have genomewide effects, 
and this lack of specificity and the lack of 
known targets mean that side effects are 
likely to be severe.” In Bestor’s view, “con-
vincing evidence of a beneficial effect of 
DNA methylation inhibitors in cancer has 
not appeared despite much effort.” He 
thinks that “the extent of pathogenic gene 
silencing by DNA methylation may have 
been greatly overestimated.”
Combining Epigenetic Drugs
Jones sees the lack of specificity in a dif-
ferent light. “The thing that you’re actu-
ally targeting, is an abnormal chromatin 
state,” says Jones. “It seems like the 
abnormal state responds most effectively 
to these kinds of drugs.” Normal epige-
netic marks—like those that inactivate 
the second X chromosome in females—
are not affected by azacytidine or other 
demethylating drugs, potentially because 
there are several mechanisms of epige-
netic regulation at work. “Abnormal chro-
matin states may respond to two drugs, 
which both affect different parts of the 
pathway and reactivate a gene more spe-lsevier Inc.cifically,” says Jones. Jones, together with 
Stephen Baylin at the Johns Hopkins Uni-
versity in Baltimore, Maryland, is devel-
oping a combination antitumor therapy 
comprising an HDAC inhibitor and a DNA 
methylation inhibitor. “It is possible,” says 
Jones, although he does not yet have 
proof of this, “that there are miscom-
binations in the pathologically silenced 
genes, which will respond to double treat-
ments.” In his view, normal genes do not 
have these miscombinations such that 
the drugs leave them untouched. “That’s 
the way I would see the future for getting 
more specificity,” says Jones.
Epigenetic drug combination therapy 
is starting to garner interest. Kapil Bhalla 
and his team have treated an acute 
myeloid leukemia cell line with a combi-
nation of the histone methyltransferase 
inhibitor DZNep (deazaneplanocin A) 
and the HDAC inhibitor panobinostat 
(developed by Novartis). Each drug alone 
reactivated pathogenically methylated 
genes such as the tumor suppressor 
p16, inducing apoptosis of 20% to 30% 
of the cancer cells. But treatment with 
both DZNep and panobinostat induced 
apoptosis of 75% of the leukemic cells. 
In a clinical trial, Bhalla’s team added 
the HDAC inhibitor entinostat twice dur-
ing a 5-azacytidine treatment regimen 
and observed slowed cancer growth in 
46% of patients. Despite this encourag-
ing finding, Bhalla points out: “We don’t 
really know what’s the molecular mecha-
nism of action of these drugs.” His team 
has demonstrated that the epigenetic 
drug combination induced reactivation 
of certain tumor suppressor genes but 
has struggled to correlate this with the 
predicted DNA demethylation pattern. “It 
might be,” he says “that we did not look 
at the critical genes that become dem-
ethylated and reactivated, and induce 
differentiation or apoptosis.” Because 
epigenetic drugs usually take several 
weeks to show their effects, Bhalla spec-
ulates that they may be acting on only 
a very small stem cell-like population in 
the tumor.
Designer Epigenetic Drugs of the 
Future
Frank Lyko at the German Cancer 
Research Center has taken a different 
approach. Starting with the crystal struc-
ture of the human DNA methyltransferase 
DNMT1, he has used rational computer 
design to come up with a direct inhibitor 
that fits into and blocks the active domain 
of the enzyme. Because this molecule 
(RG108) inhibits only one of the four 
human DNA methyltransferases, the pat-
tern of demethylation it generates in the 
genome is different from that of azacyti-
dine. “RG108 is very interesting because 
it does not require entry into DNA to do 
the job and therefore might have fewer 
side effects,” comments Jones. The char-
ity Cancer Research UK is developing 
RG108 together with the Swiss pharma 
company Roche. To increase specificity, 
Lyko and his team are now searching for 
new small-molecule inhibitors of each of 
the four human DNA methyltransferases, 
as part of a 2 year €3.5 million alliance 
between the German Cancer Research 
Center and the pharma company Bay-
erSchering. Lyko is also developing an 
azacytidine variant called CP-4200—in 
which conjugation of a lipid chain to aza-
cytidine accelerates its cellular uptake 
and activity—with Clavis Pharma in Oslo, 
Norway.
Biotech entrepreneurs are also start-
ing to become interested in the next 
wave of epigenetic drugs that alter his-
tone methylation. In 2004, Yang Shi at 
Harvard Medical School in Boston, Mas-
sachusetts, discovered the first histone 
demethylase, an enzyme that removes 
two methyl groups from the tail of his-
tone H3. “There was a dogma that his-tone methylation is not reversible,” says 
Shi, “but we showed that it is dynami-
cally regulated.” Shi, at the same time 
as Yi Zhang at the University of North 
Carolina, then identified other groups 
of histone demethylases and methyl-
transferases acting on different histone 
residues. In 2008, Yang Shi and Yi Zhang 
helped to found the biotech companies 
Constellation and Epizyme, respectively.
Another founder of Epizyme, Bob Hor-
vitz of MIT in Cambridge, Massachu-
setts, got interested in epigenetic ther-
apy through his genetic studies with the 
nematode. Looking at the consequences 
of mutations in a variety of genes encod-
ing histone methyltransferases or dem-
ethylases, he observed that they were 
“quite distinguishable.” He concluded 
that “distinct methyltransferases are not 
themselves all doing the same thing, but 
rather have distinct biological roles.” 
This suggested that histone methyltrans-
ferases and demethylases may have 
more biological specificity than HDACs, 
which are more limited in number and 
act in a more general way. “Developing 
inhibitors to different histone methyl-
transferases, you should have more tar-
geted therapies,” says Horvitz.
The specificity of a single enzyme 
within a big class is important from the 
investors’ standpoint, says Mark Levin, 
the founding CEO of Constellation. “If we 
want to build a broad platform company 
around this biology, we want to have Cell 139, Demany potential targets, so that we have a 
lot of options,” he says. Both companies 
are still searching for the appropriate 
small molecules that block histone meth-
yltransferases. Last year, Constellation 
finished three high-throughput screens 
for such small-molecule inhibitors and 
plans to complete eight this year. These 
assays are “quite unique,” says Yang 
Shi. “We have developed ways to really 
reconstitute some of the activities, using 
nucleosomes and complexes.” Com-
pared to DNA methylation, histone meth-
ylation may turn out to be a more flexible 
target, but as Frank Lyko notes, “not a 
single histone methyltransferase target 
has yet been validated in a mammalian 
model system.” When people first began 
to develop drugs to block kinases, they 
were laughed at, notes Horvitz, because 
no one could see how one kinase inhibi-
tor would not block all kinases. But it 
turned out that the active sites of kinases 
could be targeted by specific small mol-
ecules, thus enabling kinase inhibitors to 
be developed successfully. And the his-
tone methyltransferase field with only a 
handful of enzymes seems to look “even 
better than the early days of kinases,” 
says Horvitz. However, “preclinical and 
clinical studies have to be done very 
thoroughly, especially if one’s dealing 
with a new target class,” he says. “But 
on the other hand, a new target class 
opens a whole universe of new possibili-
ties for curing people.”
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